Affiliation:
1. Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Wenzhou, Zhejiang Province, China
2. Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
Abstract
Background:
Although the adjuvant therapy of bisphosphonates in prostate cancer is effective in
improving bone mineral density, it is still uncertain whether bisphosphonates could decrease the risk of Skeletal-
Related Event (SRE) in patients with prostate cancer. We reviewed and analyzed the effect of different types of
bisphosphonates on the risk of SRE, defined as pathological fracture, spinal cord compression, radiation therapy
to the bone, surgery to bone, hypercalcemia, bone pain, or death as a result of prostate cancer.
Methods:
A systemic literature search was conducted on PubMed and related bibliographies. The emphasis
during data extraction was laid on the Hazard Ratio (HR) and the corresponding 95% Confidence Interval (CI)
from every eligible Randomized Controlled Trial (RCT). HR was pooled with the fixed effects model, and
preplanned subgroup analyses were performed.
Results:
5 RCTs (n = 4651) were included and analyzed finally after screening 51 articles. The meta-analysis of
all participants showed no significant decrease in the risk of SRE when adding bisphosphonates to control group
(HR = 0.968, 95% CI = 0.874 - 1.072, p = 0.536) with low heterogeneity (I2 = 0.0% (d.f. = 4) p = 0.679). There
was no significant improvement on SRE neither in the subgroups with Metastases (M1) or Castration-Sensitive
Prostate Cancer (CSPC) (respectively HR = 0.968, 95% CI = 0.874 - 1.072, p = 0.536, I2 = 0.0% (d.f. = 4)
p = 0.679; HR = 0.954, 95% CI = 0.837 - 1.088, p = 0.484, I2 = 0.0% (d.f. = 3) p = 0.534).
Conclusion:
Our study demonstrated that bisphosphonates could not statistically significantly reduce the risk of
SRE in patients with prostate cancer, neither in the subgroups with M1 or CSPC.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Reference47 articles.
1. Ferlay,J.; Colombet,M.; Soerjomataram, I. Estimating the global cancer incidence and mortality in. 2018: GLOBOCAN sources and methods. Int, J. Cancer. 2019,144(8),1941-1953. PMID: 30350310
2. Canadian Cancer Society. Prostate cancer statistics. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/?region=sk 2017
3. Chen,W.; Zheng,R.; Zhang,S.; Zeng,H.; Xia,C.; Zuo,T.; Yang,Z.; Zou,X.; He, J. Cancer incidence and mortality in China. 2013. Cancer Lett. 2017,401,63-71. http://dx.doi.org/10.1016/j.canlet.2017.04.024 PMID: 28476483
4. Sharifi,N.; Gulley, J.L.; Dahut, W.L. An update on androgen dep-rivation therapy for prostate cancer. Endocr. Relat. Cancer. 2010,17(4),R305-R315. http://dx.doi.org/10.1677/ERC-10-0187 PMID: 20861285
5. Taylor, L.G.; Canfield, S.E.; Du, X.L. Review of major adverse effects of androgen-deprivation therapy in men with prostate can-cer. Cancer. 2009,115(11),2388-2399. http://dx.doi.org/10.1002/cncr.24283 PMID: 19399748
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献